Reviva Pharmaceuticals: Funding, Investors & Team (Sep 2026)
Reviva Pharmaceuticals, Inc. is a pharmaceutical company located in Santa Clara, California. It is publicly traded and focuses on late-stage clinical development. Reviva aims to address unmet medical needs in various areas, such as central nervous system, cardiovascular, metabolic, and inflammatory diseases. The company is led by a highly successful and experienced management team with a track record of bringing drugs to the global market. Reviva prioritizes speed and quality in its product development model and has a strong patent portfolio. They have multiple products in various stages of development. Their leading product, RP5063, has completed Phase 2 clinical trials and has shown promising results for schizophrenia and schizo affective disorder. The company has had a successful meeting with the US FDA and is now preparing for Phase 3 clinical trials for RP5063 in schizophrenia patients. Reviva also plans to develop RP5063 for other disorders such as bipolar disorder, major depressive disorder, Alzheimer's psychosis/agitation, Parkinson's psychosis, attention deficit hyperactivity disorder, and autism spectrum disorder.
Reviva Pharmaceuticals has raised $48.0M across 4 funding rounds on record, the most recent an undisclosed round of $10.0M announced in Jun 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Reviva Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Jun 2025.
Reviva Pharmaceuticals Funding Rounds
Reviva Pharmaceuticals raised $30.0M in an undisclosed round announced in Nov 2023.
6 months later, an undisclosed round of $3.0M was announced in May 2024.
3 months later, an undisclosed round of $5.0M was announced in Aug 2024.
10 months later, an undisclosed round of $10.0M was announced in Jun 2025.
Reviva Pharmaceuticals Founders and Leadership Team
Contact details for the Reviva Pharmaceuticals team: 1 of 1 has an email address on file.
Start 14-day free trial →Reviva Pharmaceuticals Funding Compared to Other Biotechnology Startups
Reviva Pharmaceuticals' latest round of $10.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Reviva Pharmaceuticals in Biotechnology and San Jose
Companies Similar to Reviva Pharmaceuticals
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Reviva Pharmaceuticals Funding FAQs
What does Reviva Pharmaceuticals do?
Reviva Pharmaceuticals, Inc. is a pharmaceutical company located in Santa Clara, California. It is publicly traded and focuses on late-stage clinical development. Reviva aims to address unmet medical needs in various areas, such as central nervous system, cardiovascular, metabolic, and inflammatory diseases. The company is led by a highly successful and experienced management team with a track record of bringing drugs to the global market. Reviva prioritizes speed and quality in its product development model and has a strong patent portfolio. They have multiple products in various stages of development. Their leading product, RP5063, has completed Phase 2 clinical trials and has shown promising results for schizophrenia and schizo affective disorder. The company has had a successful meeting with the US FDA and is now preparing for Phase 3 clinical trials for RP5063 in schizophrenia patients. Reviva also plans to develop RP5063 for other disorders such as bipolar disorder, major depressive disorder, Alzheimer's psychosis/agitation, Parkinson's psychosis, attention deficit hyperactivity disorder, and autism spectrum disorder.
How much funding has Reviva Pharmaceuticals raised?
Reviva Pharmaceuticals has raised $48.0M across 4 rounds on record. The most recent is an undisclosed round of $10.0M announced in Jun 2025.
When did Reviva Pharmaceuticals last raise funding?
Reviva Pharmaceuticals' most recent funding round on record is an undisclosed round of $10.0M, announced in Jun 2025.
Who founded Reviva Pharmaceuticals?
FundedIQ lists Laxminarayan Bhat (Founder) at Reviva Pharmaceuticals.
Where is Reviva Pharmaceuticals headquartered?
Reviva Pharmaceuticals is based in San Jose, California, United States.
How many employees does Reviva Pharmaceuticals have?
Reviva Pharmaceuticals is in the 11-50 employee band.
How does Reviva Pharmaceuticals' funding compare to other Biotechnology startups?
Reviva Pharmaceuticals' latest round of $10.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Reviva Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Reviva Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.